Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Step 4 Understand your options, compare costs, and choose with confidence
The association between weight loss medications and cardiovascular complications
Key highlights: Once-daily oral administration No food or water restrictions No injections required ~12% mean weight loss in Phase 3 trials Improvements in cardiometabolic risk markers Indication: Approved for adults with obesity, or overweight individuals with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity
J.QiZ.-Y
Plasmid concentrations for microinjections were 50 ng/l for the genes of interest and 2.5 ng/l for the injection marker, respectively
US$ 26.60
US$ 26.01
US$ 28.88
